Expect to see ASO3 or related adjuvant from GSK in experimental Coronavirus vaccines:
GSK has previously developed a pandemic vaccine platform, a system that helps to improve vaccines by strengthening the immune response in patients who receive it. In February, the company announced it was partnering with the Coalition for Epidemic Preparedness Innovations to use that platform to improve potential vaccines to the new coronavirus. As part of that collaboration, it signed an agreement with the University of Queensland, Australia, which is developing a potential vaccine. GSK has also partnered with Chinese pharmaceutical company Clover to use its adjuvant platform with that company’s COVID-19 vaccine candidate.